This review did not compare one standardized cannabis treatment against a control arm. It pooled five studies that examined cannabis exposure in people undergoing lumbar fusion and then looked at whether revision surgery occurred more often in cannabis users than in nonusers.

That distinction matters. A pooled surgical-outcomes signal can be clinically useful even when the exposure is messy, but readers need to know they are looking at an association across variable real-world studies, not a randomized experiment proving that one cannabinoid formulation harms fusion healing.

An odds ratio of 2.27 means revision surgery was reported more often among cannabis users in the combined data set. That is a meaningful signal because revision surgery after lumbar fusion is not a trivial endpoint. It implies more procedures, more recovery time, more cost, and more uncertainty for the patient.

At the same time, odds ratios can sound cleaner than the data underneath them. The paper does not tell a patient, with individualized precision, what their own absolute revision risk will be. It tells clinicians there is enough pooled signal to ask better questions before surgery rather than treating cannabis use as irrelevant.

This is the number that should slow every reader down. An I² of 95% means the included studies differed dramatically. Those differences may include who counted as a cannabis user, how often they used, whether tobacco or opioid co-use was present, and how follow-up was handled.

When heterogeneity is this high, the pooled estimate is still informative, but it becomes much less stable as a bedside rule. In practical terms, the paper supports caution and counseling more strongly than it supports certainty about mechanism or magnitude.

Observational perioperative studies are especially vulnerable to confounding. Cannabis users may differ from nonusers in pain severity, nicotine exposure, opioid use, mental health burden, socioeconomic factors, sleep disruption, or baseline function. Any of those factors can influence surgical recovery and reoperation risk.

That does not erase the signal. It does mean the cleanest defensible claim is limited: cannabis use was associated with higher revision-surgery odds in the studies reviewed. The paper cannot prove cannabis itself disrupted fusion biology or caused every excess revision event.

The most responsible clinical use of this paper is structured preoperative counseling. Patients should be asked not simply whether they use cannabis, but what product they use, how often, by what route, for what symptom, alongside what other substances, and whether they can modify exposure safely around surgery.

For clinicians, the paper supports better documentation and more deliberate risk discussion. It does not support shaming, simplistic abstinence claims without context, or overpromising that changing cannabis use alone will solve perioperative risk.

CED Clinic has already covered several spine-surgery and perioperative cannabis studies, and those signals have not all pointed in the same direction. Some earlier procedure-specific reports looked more reassuring, while others suggested higher complication burdens or higher perioperative opioid use.

That is exactly why this meta-analysis matters. It does not end the conversation, but it strengthens the case for treating cannabis exposure as a serious perioperative variable rather than a footnote. The field now needs better prospective surgical studies with standardized exposure measurement, tobacco and opioid adjustment, and procedure-specific follow-up.

The value of this paper is not that it lets anyone say, “Cannabis is clearly safe before lumbar fusion,” or, “Cannabis clearly causes failed fusion.” It does neither. What it does is make the preoperative conversation harder to avoid, because the pooled signal is large enough to matter and messy enough to require humility.

If I were counseling a patient, I would use this study to justify a more detailed discussion about product type, inhaled versus oral exposure, nicotine overlap, pain goals, and perioperative planning. That is a more defensible clinical move than pretending one meta-analysis settles the issue.

Four questions worth asking before you trust the pooled result